SUO 2017: Should Patients With Negative Multi-parametric MRI Avoid Prostate Biopsy?

Washington, DC ( Introduction: This study attempted to evaluate the detection rate and predictors of clinically significant prostate cancer (CSPCa) in patients with negative multi-parametric magnetic resonance imaging (mpMRI) prior to prostate biopsy (PBx).

Methods: The authors identified patients from an institutional board-approved database of 1500 patients. Inclusion criteria included a negative mpMRI (3T; DWI, T2W, DCE), prior to 12-core systematic PBx. Exclusion criteria included prior treatment for PCa and mpMRI performed not at the authors’ center. Negative mpMRI was defined as Prostate Imaging-Reporting and Data
System version 2 (PIRADS) score < 3. CSPCa was defined as Gleason score > 6 on PBx. mpMRIs and PBx were reviewed by an experienced uroradiologist and uropathologist, respectively.

Results: A total of 135 patients met inclusion/exclusion criteria. The median (IQR) age, PSA, prostate volume and PSA density (PSAD) were: 64 years (58-69), 5.9ng/mL (4.1-8.0), 55cc (38-79), and 0.1 ng/ml/cc (0.07-0.15), respectively. Of the patients, 48 (36%) were PBx-naive, 60 (44%) had previous negative PBx, and 27 (20%) had previous positive PBx, of those, 20 (15%)
patients were on active surveillance. The PCa (any Gleason) and CSPCa detection rate were 37.8% (51/135) and 17.0% (24/135), corresponding to a negative predictive value (NPV) of 62.2% and 83%, respectively. Patients detected with CSPCa (N=24) had smaller prostate (p=0.00036), higher PSAD (p<0.0001) and previous positive PBx (p=0.025) when compared to non-CSPCa group (N=111). Multivariable analyses showed PSAD > 0.15ng/ml/cc as an independent predictor for detection of CSPCa (p<0.01).

Conclusion: Patients with high PSA density should consider prostate biopsy even if mpMRI is negative. Prostate cancer, Gleason > 7, can be detected in 17% of the patients with negative mpMRI undergoing systematic 12-core biopsy. The authors demonstrated that PSA density > 0.15 ng/ml/cc is an independent predictor of CSPCa on biopsy. The NPV of mpMRI for clinically significant prostate cancer is 83%.

Presented by: Masakatsu Oishi, USC institue of urology, Los-Angeles, CA, USA

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, @GoldbergHanan, at the 18th Annual Meeting of the Society of Urologic Oncology, November 29-December 1, 2017 – Washington, DC

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.